Ljudböcker & E-böcker - Lyssna & läs gratis i mobilen
Novo Nordisk, driving change to defeat diabetes
Brand Week Istanbul
Novo Nordisk Norway
Cardiology Journals, Reviews, Education, Guidelines and News | Radcliffecardiology Diabetes can increase the risk of a stroke by two fold. Can GLP-1 receptor analogue-based treatment reduce the risk of a stroke in high-risk individuals with T2D?
Dr David Strain reveals the results from a post hoc analysis of LEADER, SUSTAIN 6 and PIONEER 6 trials. Discussion supported by an unrestricted educational grant from Novo Nordisk.
Cardiology Journals, Reviews, Education, Guidelines and News | Radcliffecardiology